Switch theme
Sign up to access all valuation multiples
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
1992
815
LTM Revenue $306M
LTM EBITDA $63.2M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Marksans Pharma has a last 12-month revenue of $306M and a last 12-month EBITDA of $63.2M.
In the most recent fiscal year, Marksans Pharma achieved revenue of $253M and an EBITDA of $59.1M.
Marksans Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Marksans Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $215M | $253M | XXX | XXX | XXX |
| Gross Profit | $85.0M | $108M | XXX | XXX | XXX |
| Gross Margin | 40% | 43% | XXX | XXX | XXX |
| EBITDA | $45.9M | $59.1M | XXX | XXX | XXX |
| EBITDA Margin | 21% | 23% | XXX | XXX | XXX |
| Net Profit | $21.7M | $30.9M | XXX | XXX | XXX |
| Net Margin | 10% | 12% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Marksans Pharma's stock price is INR 206 (or $2).
Marksans Pharma has current market cap of INR 93.2B (or $1.1B), and EV of INR 88.3B (or $1.0B).
See Marksans Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.1B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Marksans Pharma has market cap of $1.1B and EV of $1.0B.
Marksans Pharma's trades at 3.4x LTM EV/Revenue multiple, and 16.2x LTM EBITDA.
Analysts estimate Marksans Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Marksans Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 16.6x | XXX | XXX | XXX |
| P/E | 25.7x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | 51.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMarksans Pharma's NTM/LTM revenue growth is 18%
Marksans Pharma's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Marksans Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Marksans Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Marksans Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marksans Pharma acquired XXX companies to date.
Last acquisition by Marksans Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Marksans Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Marksans Pharma founded? | Marksans Pharma was founded in 1992. |
| Where is Marksans Pharma headquartered? | Marksans Pharma is headquartered in India. |
| How many employees does Marksans Pharma have? | As of today, Marksans Pharma has 815 employees. |
| Is Marksans Pharma publicy listed? | Yes, Marksans Pharma is a public company listed on NSE. |
| What is the stock symbol of Marksans Pharma? | Marksans Pharma trades under MARKSANS ticker. |
| When did Marksans Pharma go public? | Marksans Pharma went public in 2002. |
| Who are competitors of Marksans Pharma? | Similar companies to Marksans Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Marksans Pharma? | Marksans Pharma's current market cap is $1.1B |
| What is the current revenue of Marksans Pharma? | Marksans Pharma's last 12-month revenue is $306M. |
| What is the current EBITDA of Marksans Pharma? | Marksans Pharma's last 12-month EBITDA is $63.2M. |
| What is the current EV/Revenue multiple of Marksans Pharma? | Current revenue multiple of Marksans Pharma is 3.4x. |
| What is the current EV/EBITDA multiple of Marksans Pharma? | Current EBITDA multiple of Marksans Pharma is 16.2x. |
| What is the current revenue growth of Marksans Pharma? | Marksans Pharma revenue growth between 2023 and 2024 was 18%. |
| Is Marksans Pharma profitable? | Yes, Marksans Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
